A randomized double-blind multi-center trial of hydrogen water for Parkinson’s disease: protocol and baseline characteristics

Abstract

Background

Our previous randomized double-blind study showed that drinking hydrogen (H₂) water for 48 weeks significantly improved the total Unified Parkinson’s Disease Rating Scale (UPDRS) score of Parkinson’s disease (PD) patients treated with levodopa. We aim to confirm this result using a randomized double-blind placebo-controlled multi-center trial.

Methods

Changes in the total UPDRS scores from baseline to the 8^th, 24^th, 48^th, and 72^nd weeks, and after the 8^th week, will be evaluated. The primary endpoint of the efficacy of this treatment in PD is the change in the total UPDRS score from baseline to the 72^nd week. The changes in UPDRS part II, UPDRS part III, each UPDRS score, PD Questionnaire-39 (PDQ-39), and the modified Hoehn and Yahr stage at these same time-points, as well as the duration until the protocol is finished because additional levodopa is required or until the disease progresses, will also be analyzed. Adverse events and screening laboratory studies will also be examined. Participants in the hydrogen water group will drink 1000 mL/day of H₂ water, and those in the placebo water group will drink normal water. One-hundred-and-seventy-eight participants with PD (89 women, 89 men; mean age: 64.2 [SD 9.2] years, total UPDRS: 23.7 [11.8], with levodopa medication: 154 participants, without levodopa medication: 24 participants; daily levodopa dose: 344.1 [202.8] mg, total levodopa equivalent dose: 592.0 [317.6] mg) were enrolled in 14 hospitals and were randomized.

Discussion

This study will confirm whether H₂ water can improve PD symptoms.

Trial registration

UMIN000010014 (February, 13, 2013)

Background

In patients with Parkinson’s disease (PD), the pharmacologic replacement of dopamine and other antiparkinsonian drugs has been used for symptomatic therapy. However, none of these drugs stop or lessen the dopaminergic neuronal degeneration or the progression of the disease. Findings of increased iron and lipid peroxidation and decreased levels of reduced glutathione in the substantia nigra strongly suggest that enhanced oxidative stress is involved in the pathogenesis of PD [1, 2]. Thus, antioxidant therapies might slow the progression of PD. Molecular hydrogen (H₂) has recently been highlighted as a therapeutic and preventive antioxidant. Since the first publication [3], more than 150 papers have confirmed the efficacy of H₂ in various animal models [4]. H₂-water reduced dopaminergic neuronal cell loss in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model [5] as well as 6-hydroxydopamine did [6]. Our previous randomized double-blind study has shown that drinking 1,000 mL of H₂-water for 48 weeks significantly improved (p < 0.05) the total Unified Parkinson’s Disease Rating Scale (UPDRS) scores of patients with PD who were being treated with levodopa [7]. In the present study, we aimed to confirm these results by conducting a longer and more large-scale trial that also included patients who were not being treated with levodopa. Here, we present the design and the baseline characteristics of participants already enrolled in this study.

Methods

A placebo-controlled, randomized, double-blind, parallel-group (1:1) clinical multi-center trial was organized by the Department of Neurology of Juntendo University School of Medicine in accordance with Consolidated Standards of Reporting Trials (CONSORT) guideline. Fourteen hospitals are involved as trial centers. This trial was advertised in posters and on homepages of our clinic, and participants had to declare their intentions to participate voluntarily. The inclusion criteria required that the participants have a diagnosis of PD according to the United Kingdom Brain Bank criteria [8]. All the participants should have a modified Hoehn and Yahr staging (H & Y stage) in the on-phase between 1 and 4. For 8 weeks prior to establishing the baseline, the participants’ antiparkinsonian drugs were not changed. None of the participants have dementia (MMSE < 25) or dysphagia for water. Outpatients are preferred over admitted patients. The participants are to be older than 20 years. The exclusion criteria included the following: parkinsonism due to diseases other than PD, the presence of other serious diseases, malignant tumor(s), or adverse events caused by drugs.

The clinical study is registered at UMIN clinical trial registry (UMIN-CTR) UMIN000010014 (February 13, 2013). The Ethics Committee of the Juntendo University School of Medicine approved this study in February 2013, as did the ethics committees of other centers, and all participants provided signed informed consent forms.

Randomization and blinding

The enrolled participants have been assigned using a stratified randomization method according to their age and if they were receiving levodopa. The assignments were made by C.S. The participants and those assessing outcomes will remain blinded until all the participants have finished the protocol.

Procedures

On a daily basis, the participants will drink 1,000 mL of saturated H₂-water containing 5 mM of dissolved H₂ (using Hydrogen 7.0, supplied by Ecomo International Co., Ltd. [Fukuoka, Japan]; patent No: PCT/JP2011/063601) for 72 weeks. The placebo water is saturated with N₂. The water is contained in a 500-mL plastic bottle, and the participants will drink 2 bottles per day. The participants will drink the water within 3 h of opening the cap, because H₂ evaporates. The bottles of H₂-water or placebo water will be sent to the participants’ home every week.

The schedule of the study is shown in Fig. 1. Changes in the total UPDRS scores from baseline to the 8^th, 24^th, 48^th, and 72^nd weeks, and after the 8^th week, are evaluated. The primary endpoint of the efficacy of this treatment in PD is the change in the total UPDRS score from baseline to the 72^nd week.

Fig. 1

Schedule of enrolment, intervention, and assessment. Study period of enrolment, allocation, and baseline may coincide. It is approximately 1 week to 10 days from allocation to the first day to start shipping the water. *1: Unified Parkinson’s Disease Rating Scale. *2: Parkinson’s Disease Questionnaire-39

The changes in UPDRS part II, UPDRS part III, each UPDRS score, PD Questionnaire-39 (PDQ-39), and the H & Y stage at these same time-points, as well as the duration until the protocol is finished because additional levodopa is required or until the disease progresses, will also be analyzed. Adverse events and screening laboratory parameters (total protein, albumin, alkaline phosphatase, aspartate transaminase, alanine transaminase, serum urea nitrogen, calcium, chloride, creatinine, glucose, lactate dehydrogenase, potassium, sodium, creatinine kinase, uric acid, choline esterase, LDL-cholesterol, HDL-cholesterol, and triglyceride levels) will also be examined.

Statistical analysis

We calculated that a minimum of 95.4 participants need to be enrolled to detect a 5-point difference in the UPDRS scores between the 2 groups, with a standard deviation of the mean difference of 10, and a 2-sided alpha level of 0.05 and 80 %. Assuming a 35 % dropout, 96 participants will be required in total. A period of 72 weeks’ follow-up is a relatively long-term clinical trial in PD; hence, we assumed a 35 % dropout rate.

Variations in the endpoints between the baseline value and treatment assessment points will be compared between the groups, using a t-test or a Mann–Whitney U-test. The statistical tests are 2-sided, and the significance level is set at 0.05. The number of participants in the treatment and placebo groups who drop out due to disease progression will be analyzed using Kaplan − Meier curves and the log-rank test. Subgroup analysis (sex, and treatment with or without levodopa) will be performed.

Enrollment and data collection

One-hundred-and-seventy-eight Japanese participants with PD have already been enrolled in 14 hospitals and have been randomized, between April 1, 2013 and September 30, 2015, at their baseline visit. The participants will be followed-up for 80 weeks. The baseline characteristics are shown in Table 1. Despite extensive efforts to enroll more participants, the expected number of participants was not met, as it is difficult for some patients to consume 1000 mL water daily.

Table 1 The baseline characteristics of the study participants

Discussion

Fujita et al. have indicated that the intake of H₂-water, even after MPTP administration, reduces neurotoxic damage [5]. The findings of our previous study [7] on PD patients are in agreement with the previous results that were obtained in animal models.

Antioxidant supplements that are considered medicinal products should undergo sufficient evaluation before marketing, as they might be harmful at high doses [9]. H₂ selectively reduces •OH radicals, but not O₂⁻•, H₂O₂, or NO• [4]. It is expected that prolonged application of H₂ will have no or little adverse effects in chronic diseases. The effects of H₂ could be mediated by modulating activities and expression of various molecules, such as Lyn, ERK, p38, JNK, ASK1, Akt, GTP-Rac1, iNOS, Nox1, NF-κB, p65, Iκba, STST3, NFATc1, c-Fos, and ghrelin [10]. Iuchi et al. proposed a hypothetical model in which H₂ is linked to the modulation of Ca²⁺ signal transduction and the nuclear factor of activated T cells (NFAT) pathway via oxidized phospholipid species [11].

Our previous trial was the first randomized double-blind study of H₂-water in patients with PD [7]. H₂-water exhibited no adverse effects at a dose of 1000 mL/day in PD subjects receiving levodopa treatment. The results of the previous study will be confirmed in this longer and larger-scale study that includes patients who are not medicated with levodopa. This study will confirm the safety and tolerability of H₂-water and if H₂-water can improve PD symptoms.

Ethics approval

A randomized double-blind multi-center trial of hydrogen water for Parkinson’s disease was approved by the Ethics Committee of the Juntendo University School of Medicine, and the ethics committees of other centers.

Consent for publication

Not applicable.

Availability of data and material

Not applicable.